GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
Publication
, Journal Article
Tricoci, P; Newby, LK
Published in: Cardiol Rev
2008
Glycoprotein IIb-IIIa inhibitors provide the most benefit in patients with non-ST-elevation acute coronary syndromes and high-risk features and in those who undergo early invasive treatment. Current guidelines recommend glycoprotein IIb-IIIa inhibition in these patients but offer little guidance as to timing of initiation. Preliminary data suggest superior outcomes with upstream initiation (upon admission to a medical facility) compared with delayed initiation (in the catheterization laboratory, just before percutaneous coronary intervention). The availability of new antiplatelet and antithrombotic drugs renders even more complex the question of the best strategy.
Duke Scholars
Published In
Cardiol Rev
DOI
EISSN
1538-4683
Publication Date
2008
Volume
16
Issue
2
Start / End Page
89 / 94
Location
United States
Related Subject Headings
- Thrombolytic Therapy
- Practice Guidelines as Topic
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Aggregation Inhibitors
- Patient Selection
- Humans
- Emergency Treatment
- Drug Therapy, Combination
- Drug Administration Schedule
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Tricoci, P., & Newby, L. K. (2008). GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents? Cardiol Rev, 16(2), 89–94. https://doi.org/10.1097/CRD.0b013e31815e7213
Tricoci, Pierluigi, and L Kristin Newby. “GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?” Cardiol Rev 16, no. 2 (2008): 89–94. https://doi.org/10.1097/CRD.0b013e31815e7213.
Tricoci P, Newby LK. GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents? Cardiol Rev. 2008;16(2):89–94.
Tricoci, Pierluigi, and L. Kristin Newby. “GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?” Cardiol Rev, vol. 16, no. 2, 2008, pp. 89–94. Pubmed, doi:10.1097/CRD.0b013e31815e7213.
Tricoci P, Newby LK. GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents? Cardiol Rev. 2008;16(2):89–94.
Published In
Cardiol Rev
DOI
EISSN
1538-4683
Publication Date
2008
Volume
16
Issue
2
Start / End Page
89 / 94
Location
United States
Related Subject Headings
- Thrombolytic Therapy
- Practice Guidelines as Topic
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Aggregation Inhibitors
- Patient Selection
- Humans
- Emergency Treatment
- Drug Therapy, Combination
- Drug Administration Schedule
- Cardiovascular System & Hematology